Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

UTXC:506/HIB **Applicants**

Serial No. 09/026,459

Hong-Ji Xu, Shi-Xue Hu, William F. Benedict

and Yunli Zhou

Atty. Docket No.

Filing Date: February 19, 1998 Group:

1635 - (632

SEP 2 8 1998

(Use several sheets if necessary)

INFORMATION DISCLOSURE STATEMENT

U.S. Patent Documents

Foreign Patent Documents See Page 1

Other Art See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.
			-				

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
~	В1	WO 94/21115	09-29-94	PCT			
2	B2	WO 95/07708	03-23-95	PCT			
0	В3	WO 96/20207	07-04-96	PCT			
1	23	1, 0 7 3 1 2 0 2 0 1	0.0130				

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
W.	C32	Antelman et al., "Engineered mutants of pRB with improved growth suppression potential," Oncogene 15:2855-2866, 1997.
	C33	Hiebert, "Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRB-mediated growth suppression," <i>Mol. Cell. Biol.</i> 13:3384-3391, 1993.
	C34	International Search Report, dated September 9, 1998 (PCT/US98/03041) (Atty. Dkt. No. UTFC:506P).
	C35	Qian et al., "Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding," Mol. Cell. Biol. 12:5363-5372, 1992.
	C36	Qin et al., "Identification of a growth suppression domain within the retinoblastoma gene product," Genes Dev. 6:953-964, 1992.
	C37	Zhou et al., "Mechanisms for the enhanced tumor cell growth suppression by a N-terminal truncated RB protein," Proceedings of the American Association for Cancer Research, 87th Annual Meeting, 37:594-595, 1996.

Examiner:

Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (modified)

Atty. Docket No. UTXC:506/HIB

Serial No. 09/026,459

Eist of Patents and Publications for Applicant's

Applicants

Hong-Ji Xu, Shi-Xue Hu, William F. Benedict

and Yunli Zhou Filing Date:

Group: 1635- 1632

(Use several sheets if necessary)

1998 INFORMATION DISCLOSURE STATEMENT

February 19, 1998

Other Art

U.S. Patent Documents See Page 1

Foreign Patent Documents

See Page 1-3

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.
W	Al	5,578,701	11/26/96	Lee et al.	530	391.3	
m	A2	5,496,731	03/05/96	Xu et al.	435	320.1	
0	A3	4,942,123	07/17/90	Lee et al.	435	6	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
m	C1	Benedict <i>et al.</i> , "Role of the retinoblastoma gene in the initiation and progression of human cancer," <i>J. Clin. Invest.</i> , 85:988-993, 1990.
	C2	Bookstein <i>et al.</i> , "Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene," <i>Science</i> , 247:712-715, 1990.
	C3	Cance et al., "Altered expression of the retinoblastoma gene product in human sarcomas," New Engl. J. Med., 323:1457-1462, 1990.
	C4	Friend <i>et al.</i> , "A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma," <i>Nature</i> , 323:643-646, 1986.
	C5	Friend et al., "Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: Organization of the sequence and its encoded protein," <i>Proc. Natl. Acad. Sci. USA</i> , 84:9059-9063, 1987.
W	C6	Fung et al., "Structural evidence for the authenticity of the human retinoblastoma gene," Science, 236:1657-1660, 1987.

Examiner:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (modified)		Atty. Docket No.	Serial No.	
		UTXC:506/HIB	09/026,459	
List of Patents and Publications for	Applicant's	Applicants		
		Hong-Ji Xu, Shi-Xue Hu, William F. Benedict		
INFORMATION DISCLOSURE S	TATEMENT	and Yunli Zhou		
		Filing Date:	Group	
(Use several sheets if necess	sary)	February 19, 1998	1635 1632	
U.S. Patent Documents Foreign F		Patent Documents	Other Art	
See Page 1			See Page 1-3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
ml	C7	Goodrich and Lee, "Molecular characterization of the retinoblastoma susceptibility gene," [Review] <i>Biochimica et Biophysica Acta</i> , 1155:43-61, 1993.
	C8	Huang et al., "Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells," Science, 242:1563-1566, 1988.
	C9	Li et al., "Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro," Oncogene, 13:2379-2386, 1996.
	C10	Logothetis et al., "Altered retinoblastoma protein expression and known prognostic variables in locally advanced bladder cancer," J. Natl. Cancer Inst., 84:1256-1261, 1992.
	C11	Madreperla <i>et al.</i> , "Intraocular tumor suppression of retinoblastoma gene-reconstituted retinoblastoma cells," <i>Cancer Res.</i> , 51:6381-6384, 1991.
	C12	McGee <i>et al.</i> , "Structure and partial genomic sequence of the human retinoblastoma susceptibility gene," <i>Gene</i> , 80:119-128, 1989.
	C13	Mittnacht <i>et al.</i> , "Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation," <i>EMBO J.</i> , 13:118-127, 1994.
	C14	Ookawa et al., "Reconstitution of the RB gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations," <i>Oncogene</i> , 8:2175-2181, 1993.
	C15	Riley et al., "The retinoblastoma protein: more than a tumor suppressor," [Review] Annual Review of Cell Biology, 10:1-29, 1994.
	C16	Stein <i>et al.</i> , "Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts," <i>Science</i> , 249:666-669, 1990.
	C17	Wang et al., "The retinoblastoma tumor suppressor protein," [Review] Advances in Cancer Res., 64:25-85, 1994.
	C18	Weinberg, "The retinoblastoma protein and cell cycle control," [Review] <i>Cell</i> , 81:323-330, 1995.
	C19	Wills et al., "P56, a truncated form of RB, functions as a more potent regulator of cell cycle growth than full-length RB," Cancer Gene Therapy, Abstract, 2:339, 1995.
ar	C20	Xu <i>et al.</i> , "Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas," <i>Cancer Res.</i> , 51:2735-2739, 1991.

	<u> </u>		
Examiner:	Date Considered:	275	 Ø)

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (modified)		Atty. Docket No.	Serial No.	
(modifica)		UTXC:506/HIB	09/026,459	
List of Patents and Publications for	r Applicant's	Applicants Hong-Ji Xu, Shi-Xue Hu, William F. Benedict and Yunli Zhou		
INFORMATION DISCLOSURE S	STATEMENT			
		Filing Date:	Group:	
(Use several sheets if necessary)		February 19, 1998	1635 1632	
U.S. Patent Documents	Foreign	Patent Documents	Other Art	
See Page 1			See Page 1-3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
m	-C21	Xu et al., "Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma," J. Natl. Cancer Inst., 86:695-699, 1994.
	C22	Xu, "Altered retinoblastoma (RB) protein expression in human malignancies," <i>Advances in Anatomic Pathology</i> , 2:213-226, 1995.
	C23	Xu et al., "Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein," <i>Proc. Natl. Acad. Sci. USA</i> , 91:9837-9841, 1994.
	C24	Xu, et al., "Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein," Cancer Res. (Advances in Brief), 56:2245-2249, 1996.
	C25	Xu et al., "Factors affecting long-term stability of Moloney murine leukemia virus-based vectors," Virology, 171(2):331-341, 1989.
	C26	Xu <i>et al.</i> , "Intraocular tumor formation of RB reconstituted retinoblastoma cells," <i>Cancer Res.</i> , 51:4481-4485, 1991.
	C27	Xu et al., "Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level," <i>Oncogene</i> , 6:1139-1146, 1991.
	C28	Xu et al., "Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition," Oncogene, 15:2589-2596, 1997.
	C29	Xu, "Strategies for approaching retinoblastoma (RB) tumor suppressor gene therapy," in Advances in Pharmacology, Gene Therapy, Volume 1, Thomas August, ed., 1996.
	C30	Xu et al., "The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells," <i>Oncogene</i> , 4:807-812, 1989.
M	C31	Zhou <i>et al</i> , "Further characterization of retinoblastoma gene-mediated cell growth and tumor suppression in human cancer cells," <i>Proc. Natl. Acad. Sci. USA</i> , 91:4165-4169, 1994.

	1)		
Examiner:	mM	Date Considered:	2/25/0

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.